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Value to the Conventional Glasgow Outcome Scale?
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Gillian S. McHugh,1 Bob Roozenbeek,2,4 Andrew I.R. Maas,4 and Gordon D. Murray1
Abstract
The Glasgow Outcome Scale (GOS) is firmly established as the primary outcome measure for use in Phase III
trials of interventions in traumatic brain injury (TBI). However, the GOS has been criticized for its lack of
sensitivity to detect small but clinically relevant changes in outcome. The Glasgow Outcome Scale-Extended
(GOSE) potentially addresses this criticism, and in this study we estimate the efficiency gain associated with
using the GOSE in place of the GOS in ordinal analysis of 6-month outcome. The study uses both simulation and
the reanalysis of existing data from two completed TBI studies, one an observational cohort study and the other
a randomized controlled trial. As expected, the results show that using an ordinal technique to analyze the GOS
gives a substantial gain in efficiency relative to the conventional analysis, which collapses the GOS onto a binary
scale (favorable versus unfavorable outcome). We also found that using the GOSE gave a modest but consistent
increase in efficiency relative to the GOS in both studies, corresponding to a reduction in the required sample
size of the order of 3–5%. We recommend that the GOSE be used in place of the GOS as the primary outcome
measure in trials of TBI, with an appropriate ordinal approach being taken to the statistical analysis.
Key words: clinical trial; Glasgow Outcome Scale-Extended; Glasgow Outcome Scale; ordinal analysis; outcome;
traumatic brain injury
Introduction
The Glasgow Outcome Scale (GOS) was developed byJennett and Bond (1975), and has since become firmly
established as the primary outcome measure used in the
majority of Phase III trials in traumatic brain injury (TBI).
Unfortunately the development of interventions to treat TBI
has been hugely disappointing. In spite of very promising
preclinical data on a range of neuroprotective agents, none of
the major Phase III trials reported to date have shown con-
vincing evidence of effectiveness over a broad class of TBI
patients (Maas et al., 2010). The reasons why the results have
been so disappointing have been widely debated, and one
possible explanation is that the GOS lacks the sensitivity to
detect small but clinically relevant treatment effects.
In response to the perceived lack of sensitivity of the GOS,
Jennett and associates (1981) developed the GOSE, an ex-
tended version of the GOS. While in principle the extended
scale should offer greater sensitivity to detect changes in
outcome, potential gains could be lost if the extended scale
introduces more inter-observer variability. The aim of this
article is to evaluate whether the GOSE adds value to the GOS
as an outcome measure in head injury trials.
The Glasgow Outcome Scales
The original Glasgow Outcome Scale has five ordered ca-
tegories: Death, Vegetative State, Severe Disability, Moderate
Disability, and Good Recovery. Although the GOS has been
widely adopted as the preferred instrument for assessing
outcome after TBI, it has been subject to criticism over the
years (Anderson et al., 1993; Gouvier et al., 1986; Hall et al.,
1985; Maas et al., 1983). It can be argued that five outcome
categories are too few to represent the wide range of mental
and physical handicaps a patient can suffer following TBI.
The GOSE scale splits each of Severe Disability, Moderate
Disability, and Good Recovery into lower and upper cate-
gories to allow for greater differentiation between the levels of
recovery that can be achieved. Several other extended scales
have been suggested in the past, but have not been widely
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adopted (Horne and Schemitsch, 1989; Livingston and Li-
vingston, 1985; Maas et al., 1983; Smith et al., 1979).
Traditionally, TBI trials have been analyzed by grouping
the GOS into two categories: Unfavorable (Death, Vegetative
State, or Severe Disability) versus Favorable (Moderate Dis-
ability or Good Recovery). Such a dichotomization of an or-
dinal scale discards potentially relevant information (Altman
and Royston, 2006), and in particular in our context would
abolish any distinction between the GOS and the GOSE. Re-
cent work reported by the IMPACT group (McHugh et al.,
2010) has shown that appropriate statistical methods can be
applied to analyze the full ordinal GOS scale, leading to an
analysis which substantially increases the statistical effi-
ciency. For a given sample size, an ordinal analysis can detect
a smaller treatment effect than can be done using conven-
tional dichotomous analysis. Thus in this paper we evaluate
whether ordinal analysis of the GOSE leads to further effi-
ciency gains over and above ordinal analysis of the GOS.
The IMPACT database
This work was undertaken by the IMPACT (International
Mission for Prognosis and Analysis of Clinical Trials in TBI)
group andwas funded partly by the U.S National Institutes of
Health. The IMPACT group is a collaboration of researchers
from Belgium, The Netherlands, the U.K. and the U.S.A. See
http://www.tbi-impact.org/ for more information, or Maas
and associates (2010) for a broad overview of the IMPACT
work to date.
The IMPACT study group has dedicated significant re-
sources to collating data from various TBI studies into one
large database. Not all of the studies used the same formats
for recording information, so merging the data was not
straightforward. Currently the database contains data on al-
most 12,000 patients. This is a combination of four observa-
tional studies and 11 randomized controlled trials (RCTs). The
development of the IMPACT database has been described by
Marmarou and colleagues (2007).
This particular analysis is based on two of the studies in the
IMPACT database with GOSE data available (Table 1). The
APOE study (Teasdale et al., 2005) was a cohort study with
patients recruited from consecutive head injury admissions to
the regional Neurosurgical Unit for the West of Scotland. The
study was designed to investigate the hypothesis that pos-
session of the APOE e4 allele is associated with poorer out-
come after acute head injury. The PHARMOS study (Maas
et al., 2006) was an international multi-center randomized
clinical trial that evaluated the efficacy and safety of dex-
anabinol in severe TBI.
Methods
Ordinal analysis
In this studywe use two ordinal analysis approacheswhich
have been described in detail in previous IMPACT publica-
tions (Maas et al., 2010; McHugh et al., 2010). The propor-
tional odds model (Bolland et al., 1998; McCullagh, 1980) in
effect estimates the odds ratio associated with each potential
dichotomy of an ordinal outcome scale, and leads to a pooled
estimate, assuming that each odds ratio is equal to an overall
common odds ratio. This estimated common odds ratio can be
thought of as a measure of the shift of outcome over the entire
ordinal scale that is associated with an intervention or a
prognostic marker.
The sliding dichotomy approach is based on grouping
patients into subgroups reflecting baseline risk, on the basis of
a prognostic model.Within each prognostic group themedian
observed outcome category represents the expected outcome,
and the impact of an intervention or a prognostic marker is
evaluated in terms of its impact on increasing the proportion
of outcomes which are better than would be expected, given
the baseline prognostic risk. The estimated sliding dichotomy
odds ratio can be thought of as a measure of how much out-
come is better than expected over the entire ordinal scale in
association with an intervention or a prognostic marker.
Both of these ordinal methods have been assessed using an
extensive set of simulations and were found to be highly ef-
ficient in comparison to a basic dichotomization of the GOS
(McHugh et al., 2010). Reductions in sample size of the order
of 40% were shown, with the proportional odds model gen-
erally outperforming the sliding dichotomy approach. The
authors found it difficult to recommend a method, as they
both had their strong points: the proportional odds model
produced the larger efficiency gains, but the sliding dichot-
omy had arguably more clinical appeal.
When using the GOS or GOSE in ordinal analyses it is
generally accepted that the categories Death and Vegetative
State should be pooled for statistical and clinical reasons. These
include the fact that there are usually a low number of patients
in the Vegetative State category, and also that Vegetative State
could never be regarded as a favorable outcome, even if the
baseline prognosis is strongly adverse. Therefore the GOS was
reduced to a four-category outcome and the GOSE to a seven-
category outcome. The conventional dichotomized GOS was
included to act as a reference technique.
Statistical analysis
In order to compare the GOS and GOSE we used the pre-
viously mentioned PHARMOS and APOE datasets. For the
PHARMOS study we investigated the sensitivity of the dif-
ferent approaches in estimating the effect of the randomized
treatment, and for the APOE study the impact of possession of
an e4 allele was taken as the treatment effect. Two types of
investigations were carried out: a standard error analysis and a
simulation study. Patients with a missing outcome measure
were not included in the analyses. Any children in the APOE
study were also excluded. These exclusions gave us the
Table 1. Details of the Studies Used in the Analyses
APOE PHARMOS
Study year 1996–1999 2001–2004
Study type Cohort RCT
Patients (n) 984 861
Age range (years) 0–93 16–66
Time window N/A £6 h
Centers (n) 1 86
Mortality (%) 13 17
Unfavorable
outcome (%)
34 51
Reference Teasdale et al. (2005) Maas et al. (2006)
RCT, randomized controlled trial.
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following patient totals: PHARMOS (n= 856)with an age range
of 16–66 years, and APOE (n= 714) with an age range of 16–93
years.
Standard error analysis. This method involved fitting
different models for each outcome scale and examining the
standard error of the estimated treatment effect. We expected
to observe a decrease in the standard error as the number of
categories in the outcome scale increased. There are potential
problems in comparing standard errors for treatment effects
in non-linear models (Ford and Norrie, 2002; Robinson and
Jewell, 1991), with the counter-intuitive finding that covariate
adjustment typically increases the standard error of an esti-
mated treatment effect. However, in our context and under
the assumption of proportional odds the binary logistic re-
gression model and proportional odds models are estimating
what is fundamentally the same parameter.
We used PROC LOGISTIC in SAS to fit three different
models (SAS 9.2, SAS System for Windows; SAS Institute
Inc., Cary, NC). For both sets of data the models were fit-
ted three times with increasing numbers of covariates: (1)
No covariates + treatment variable; (2) Three covariates
(age, Glasgow Coma Scale motor score, and pupillary re-
action) + treatment variable; and (3) Seven covariates (age,
Glasgow Coma Scale motor score, pupillary reaction, CT
scan classification, traumatic subarachnoid hemorrhage,
hypoxia, and hypotension) + treatment variable (Murray
et al., 2007; Steyerberg et al., 2008).
Simulation study. The second analysis method involved
running a series of simulations to investigate possible reduc-
tions in sample size for the four-category GOS and the seven-
category GOSE, using a basic chi-squared analysis of the
dichotomized GOS as the reference level. A detailed descrip-
tion of a similar simulation study can be found inMcHugh and
associates (2010). A summary of the steps involved is as
follows.
 Simulate an outcome on the GOSE scale for 400 randomly-
selected patients from the two datasets using their baseline
data. This generates the placebo group.
 Repeat the same process for another 400 patients, but
this time incorporating a treatment effect. The treatment
effect was calibrated to ensure a 5% absolute increase in
the proportion of patients with a favorable outcome.
This step generates the intervention group.
 Each simulation scenario is repeated 1000 times and a
reduction in sample size is calculated from the output.
The scenarios are also analyzed for the four-category
GOS, which is obtained by collapsing the GOSE.
 The simulation scenarios are different combinations of
analysis methods and numbers of covariates. Methods
include a chi-squared analysis for the dichotomous
GOS, and proportional odds and sliding dichotomy
analyses for the four- and seven-category scales.
The findings are expressed in terms of the percent reduc-
tion in sample size that can be achieved without loss of sta-
tistical power, as explained in detail by Hernandez and
colleagues (2006).
Results
Standard error analysis
As expected (McHugh et al., 2010), there is a substantial
efficiency gain when going from the conventional binary
analysis to an ordinal analysis of the GOS (Table 2). There is
then a further efficiency gain when going from the GOS to the
GOSE. To quantify the difference between the outcome scales
into a more meaningful measure, reductions in sample size
have been calculated using the dichotomized GOS as the
reference level. The four-category GOS shows a 20–40% re-
duction in sample size relative to the dichotomous analysis,
depending on which model and dataset is used. The GOSE
shows a modest but consistent gain over the four-category
GOS, with a 23–43% reduction. We also note, as discussed
earlier, that covariate adjustment leads to an increase in the
standard error of the treatment effect.
Simulation study
Looking at the simulation study results (Fig. 1), we find that
there are larger reductions in sample size in every simulation
Table 2. Standard Error of the Treatment Effects and the Associated Reductions in Sample Size
(Using the Dichotomized GOS as the Reference Level)
PHARMOS APOE
Model and
outcome scale
Estimated
treatment effect
Standard
error
Reduction in
sample size (%)
Estimated
treatment effect
Standard
error
Reduction in
sample size (%)
No covariate
GOS (2 category) 0.0193 0.1368 Reference 0.0863 0.1617 Reference
GOS (4 category) 0.0498 0.1224 19.9 - 0.0120 0.1424 22.4
GOSE (7 category) 0.0576 0.1200 23.1 0.0492 0.1403 24.7
3 Covariates
GOS (2 category) - 0.0235 0.1432 Reference 0.3054 0.1895 Reference
GOS (4 category) 0.0369 0.1243 24.7 0.1342 0.1490 38.2
GOSE (7 category) 0.0508 0.1214 28.1 0.2079 0.1449 41.5
7 Covariates
GOS (2 category) - 0.0113 0.1482 Reference 0.2929 0.1933 Reference
GOS (4 category) 0.0539 0.1258 27.9 0.1148 0.1502 39.6
GOSE (7 category) 0.0697 0.1223 31.9 0.1875 0.1454 43.4
GOS, Glasgow Outcome Scale; GOSE, Glasgow Outcome Scale-Extended.
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scenario when using the seven-category GOSE compared to
the four-category GOS. Tying in closely with the results from
the standard error analysis, there is typically an additional
3–5% reduction in sample size when using the GOSE com-
pared to the GOS. These gains are again over and above the
substantial efficiency gain obtainedwhen going from a binary
analysis to an ordinal analysis of the GOS. Another clear
finding is that the proportional odds approach tends to per-
form better than the sliding dichotomy approach, a pattern
also seen byMcHugh and colleagues (2010). It is also apparent
in both Table 2 and Figure 1 that larger percentage reductions
in sample size are achieved with the APOE study than with
the PHARMOS trial in every scenario. This is again consistent
with the findings of McHugh and colleagues (2010), that
greater efficiency gains tended to be achieved in cohort
studies with broad entry criteria than in randomized trials
with tightly defined entry criteria.
Discussion
Two main conclusions may be drawn from our results.
First, as has been shown previously (McHugh et al., 2010), it is
clear that ordinal analysis of the four-category GOS yields
substantial efficiency gains relative to the conventional di-
chotomous analysis. Second, using the seven-category GOSE
gives modest but consistent efficiency gains over and above
those achieved by the use of the four-category GOS. These
additional gains correspond to a sample size reduction of the
order of 3–5%. In our opinion such an additional gain easily
justifies the additional effort required to assess outcome using
the full GOSE in place of the GOS.
In these analyses an important point we had to consider
was how to collapse the eight-category GOSE. We chose to
group Death and Vegetative State together to form a seven-
category scale. An alternative would have been to group
Death, Vegetative State, and Lower Severe Disability together
to form a six-category scale as used in the original analysis of
the PHARMOS trial (Maas et al., 2006). In a sensitivity anal-
ysis we repeated the analyses described above using the six-
category GOSE, and in general this approach was inferior to
using the seven-category scale.
Ordinal analysis using the proportional odds model or the
sliding dichotomy does require a greater degree of statistical
sophistication than that required for a conventional binary
analysis. However, this has not prevented such approaches
from being used in practice (Maas et al., 2006; Sandset et al.,
2011). An alternative approach to the analysis of the GOS has
been suggested by Aoki and associates (1998). Based on in-
terviews with doctors, nurses, and medical students, they
assigned a numerical utility to each level of the GOS, allowing
the ordinal scale to be mapped onto an interval scale relating
to quality of life. It is not clear, however, whether this ap-
proach would achieve the efficiency gains that have been
demonstrated for the proportional oddsmodel and the sliding
dichotomy.
Any potential efficiency gains that would result from an
extended outcome scale could be lost if the inter-observer
variability increases along with the length of the scale. In
FIG. 1. Numbers 1 to 4 on the horizontal axis correspond to following methods: 1, proportional odds, treatment only; 2,
proportional odds, treatment + covariates; 3, sliding dichotomy, treatment only; and 4, sliding dichotomy, treat-
ment + covariates. ‘‘Treatment only’’ means that the final analysis model contained the treatment variable only, while
‘‘Treatment + covariates’’ means that the final analysis model contained the treatment variable plus covariates (3 or 7). See the
statistical analysis section for a list of the covariates used. GOS, Glasgow Outcome Scale; GOSE, Glasgow Outcome Scale-
Extended.
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order to address how best to assess the GOSE, Wilson and
colleagues (1998) developed a set of structured interview
questions. A study carried out by the same authors demon-
strated kappa values of 0.89 for the GOS and 0.85 for the
GOSE. In comparison to the results shown by Maas and as-
sociates (1983), there was a substantial improvement in the
degree of inter-observer agreement when using the structured
interview.
Further evidence in support of the GOSE can be found in a
subsequent article by Wilson and associates (2000), in which
the relationship between outcome scales and other measures
of outcome and clinical status was explored. The results
suggest that both the GOS and GOSE show good agreement
with injury severity, rating of disability, cognitive testing,
perception of health, and symptoms reported by people with
head injury and their relatives. In a similar vein, Levin and
colleagues (2001) explored the relationship of the scales to
functional and neuropsychological outcome measures. They
found that the GOSE performed better than the GOS, a result
that the authors believe will make the GOSE more sensitive
than the GOS to interventions, especially when measuring
changes over time.
In conclusion we recommend that the GOSE should be
recorded in future studies, given the potential for increased
sensitivity relative to the GOS. To realize this potential it is
essential that ordinal analysis is used. Every effort should be
taken tominimize inter-observer variability, including the use
of structured interviews. Regular feedback and training ses-
sions can serve to highlight the importance of taking great
care to standardize the assessment of the GOSE.
This study can be seen as the final piece of the set of rec-
ommendations for trial conduct and analysis in TBI (Maas
et al., 2010). In summary, we recommend that for future Phase
III trials in TBI: (1) entry criteria should be broad, to include all
patients who would be expected to benefit from the inter-
vention being tested; (2) the analysis should be adjusted for
key baseline covariates; (3) ordinal analysis should be used,
based on either the proportional odds model or the sliding
dichotomy; and (4) the GOSE should be used in preference to
the GOS, since with an ordinal analysis this can yield a further
modest but clinically-relevant increase in statistical efficiency
that outweighs the additional effort required to assess the
GOSE instead of the GOS.
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